Skip to content
Buy This GLP
← Research
Evidence

Who Funds GLP-1 Research? How to Read Study Disclosures

Author financial ties, trial sponsorship and economic model funding answer different questions. Here is how three papers disclose them.

Editorial profile: Carla MedinaBuy This GLP Editorial Team4 min read
60 comparisons across 56 randomized trialsorlistat22semaglutide14liraglutide11tirzepatide6naltrexone/bupropion5phentermine/topiramate2

A research paper can disclose funding for the work and separate financial relationships for its authors. For example, our guide to the semaglutide cost model for MASH explains how assumptions and sponsorship fit together. Read the funding statement alongside the methods and results.

What a review disclosed

A 2025 systematic review included a sample of 60,307 participants from 56 obesity medication trials [1]. Of the 60 comparisons, 14 involved semaglutide and six involved tirzepatide. Some trials contributed multiple comparisons. The competing interests section describes author ties including advisory fees, speaking fees and research grants. Those disclosures do not identify a sponsor for every trial in the review.

What manufacturers supported in two economic models

Two authors of a US semaglutide MASH model worked for Novo Nordisk, and the third worked for a company Novo contracted [2]. The model estimated $19,911 per additional quality-adjusted life year compared with standard care. That is a projected cost-effectiveness ratio for a defined patient group.

Another analysis used a clinical trial to project costs beyond the period that researchers observed [3]. The tirzepatide lifetime cost model includes authors affiliated with Eli Lilly. A lifetime projection depends on drug prices, how long people stay on treatment and how the model estimates later complications.

Frequently asked

Does this review show who funds most GLP-1 research?
The review covers a defined set of obesity medication trials. Its author disclosures do not measure sponsor prevalence across the field.
How do I check who supported a study?
Read the funding statement, author affiliations and competing interests section. Look for the sponsor’s stated role in designing or analyzing the work.
Why do assumptions matter in cost models?
A projection can change when drug prices, treatment duration or the expected rate of complications change.

Sources

  1. [1] McGowan B, et al. (2025). A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults Nature Medicine. PMID 41039116
  2. [2] McGovern AJ, et al. (2026). A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States PharmacoEconomics. PMID 42503575
  3. [3] Johansson E, et al. (2026). Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial Journal of Medical Economics. PMID 42012820

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence